Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

Core Insights - Humanetics Corporation is developing BIO 300, a novel radioprotective agent aimed at preventing acute radiation syndrome, with support from the Department of Defense [1][3] - Lifecore Biomedical has been selected to provide contract development and manufacturing services for BIO 300, including technology transfer and analytical method activities [1][2] - The collaboration highlights the innovation within Minnesota's life sciences sector and aims to provide critical protection against radiation exposure for military personnel and civilians [2] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products, with over 40 years of experience [4] - Humanetics Corporation focuses on the discovery and development of proprietary drugs for urgent medical needs, particularly in radiation countermeasures and oncology [5] Financial Support - The development of BIO 300 is supported by a grant of $5,132,520 from the Department of Defense through the Peer Reviewed Medical Research Program [3]